Showing 4421-4430 of 6983 results for "".
- NEWA®, Home-Use RF Skin-Care System Launches From Eclipsehttps://practicaldermatology.com/news/newa-home-use-rf-skin-care-system-launches-from-eclipse/2458350/The DIY at-home beauty device market is exploding, and Eclipse Aesthetics®, LLC., in partnership with EndyMed Medical Ltd., is upping the ante with the
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con
- ASDS Honors Awarded and New Board Members Electedhttps://practicaldermatology.com/news/asds-honors-and-new-board-members/2458362/Four members of the American Society for Dermatologic Surgery (ASDS) recently were recognized with the President’s Award for their extraordinary contributions to the Society or the specialty as a whole, and the ASDS awarded Jeanean D. Carruthers, MD, of Vancouver, British Columbia, Canada,
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies
- Food Allergy Linked to Early Exposure Through Broken Skinhttps://practicaldermatology.com/news/food-allergy-linked-to-early-exposure-through-broken-skin/2458369/Early exposure to a food allergen through broken skin might prompt the development of food allergy, according to new research in Allergy and Asthma Proceedings. This theory gained further support from a recent study that fo
- US Attorney Announces Charges Against Two Executives Tied to Philidor Pharmacy Schemehttps://practicaldermatology.com/news/us-attorney-announces-charges-against-two-executives-tied-to-philidor-pharmacy-scheme/2458373/The US Attorney’s Office, Southern District of New York has charged two executives in connection with the Philidor Pharmacy scheme that instigated a stock value plunge at Valeant when it was revealed last year. The US Attorney’s office will hold a press conference today to
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu